QPS, a GLP/GCP-compliant contract research organization (CRO) supporting discovery, preclinical and clinical drug development, and expanding its U.S.-based Phase I clinical trial capabilities to support the growing needs of its pharmaceutical, biotechnology and CRO partners.
A team of researchers from the Dr. Rath Research Institute in California has developed a cancer vaccine effective in reducing tumor growth.
Baxter International Inc. (NYSE:BAX), a global innovator in renal care, highlighted findings from HDx (expanded hemodialysis) and peritoneal dialysis (PD) studies presented at the American Society of Nephrology (ASN): Kidney Week, Oct. 23-28, showing how novel renal care technologies are positively impacting patient care and clinic efficiency.
In January 2018, doctors at the Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center implemented a breakthrough protocol for ovarian cancer.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the strengthening of its intellectual property (IP) portfolio, as it has successfully passed the patent opposition period in Europe..
Keystone Folding Box Co., a designer and cGMP manufacturer of paperboard packaging solutions, has developed a modified, customizable version of its Ecoslide-RX prescription blister package to address the nation's ongoing opioid epidemic.
The availability of, and demand for, at-home diagnostic products is on the rise – the market for point-of-care diagnostics is projected to reach $37 billion by the end of 2021.
Evoqua Water Technologies Corp. has completed an exclusive sales and distribution agreement with Horizon Solutions, LLC (“Horizon”) to expand local service in Puerto Rico.
The NSW Medical Device Fund has awarded AUD$500,000 to Indee Labs to partner with the University of Sydney to trial its technology to manufacture curative therapeutics for blood cancer.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) reported today the first participant's initial visit in a pivotal clinical efficacy Phase 3 trial of the M-001 universal flu vaccine candidate.